Background
Conestat alfa, a recombinant C1-inhibitor concentrate (rhC1-INH), is a novel therapeutic option for the acute treatment of hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE).
Methods
We analyzed 137 edematous episodes requiring acute treatment and occurring in 6 C1-INH-HAE patients. The patients were treated at home with a dose of 2100 U rhC1-INH per occasion. They recorded the time of rhC1-INH administration, time until the symptoms stopped worsening, time to the onset of symptom relief and to the complete resolution of symptoms. Any side effects were recorded in addition. Symptom severity and patient satisfaction were measured with a visual analogue scale (VAS). None of the patients experienced a recurrence of the attack, or drug-related systemic adverse events. The mean VAS score of patient satisfaction was 95.8.
Conclusions
Home treatment with rhC1-INH was an effective and well-tolerated therapy for all types of HAE attacks. Early treatment of the attacks resulted in better outcomes.
